International Journal of Trend in Scientific Research and Development (IJTSRD)
Volume 9 Issue 6, Nov-Dec 2025 Available Online: www.ijtsrd.com e-ISSN: 2456 – 6470

Development and In-Vitro Assessment of Clarithromycin-Encapsulated Floating Microballoons for Targeted Gastric Drug Delivery

Atul Raj[1], Mr. Ashvani Kumar[2]

[1]M.Pharm, [2]Associate Professor,
[1,2]Department of Pharmaceutics, Institute of Pharmaceutical Sciences and Research, Unnao, Uttar Pradesh, India

ABSTRACT

Gastric ulcers and Helicobacter pylori–associated infections remain significant clinical challenges, often requiring sustained gastric drug exposure for effective therapy. Clarithromycin, a key antibiotic used in H. pylori eradicate ion regimens, exhibits limitations such as short gastric residence time and variable bioavailability following conventional oral administration. The present study aimed to develop and evaluate a gastroretentive floating microballoon system of clarithromycin to enhance gastric retention, controlled drug release, and therapeutic efficacy.

Floating microballoons of clarithromycin were prepared using the emulsion solvent evaporation technique employing suitable polymers and excipients. The formulated microballoons were characterized for particle size, percentage yield, drug entrapment efficiency, surface morphology using scanning electron microscopy (SEM), in-vitro buoyancy, and in-vitro drug release behavior. Compatibility between the drug and excipients was confirmed by Fourier transform infrared (FTIR) spectroscopy. The prepared microballoons exhibited spherical shape with hollow internal structure, good flow properties, and satisfactory entrapment efficiency. In-vitro buoyancy studies demonstrated prolonged floating behavior, indicating effective gastric retention. Drug release studies revealed a sustained release profile over an extended period, suggesting controlled diffusion of clarithromycin from the polymeric matrix.

The results indicate that clarithromycin-loaded floating microballoons represent a promising gastroretentive drug delivery system capable of enhancing gastric residence time and improving bioavailability. This approach may offer an effective alternative to conventional oral dosage forms for targeted gastric drug delivery in the management of peptic ulcer disease and H. pylori infections.

How to cite this paper: Atul Raj | Mr. Ashvani Kumar "Development and In-Vitro Assessment of Clarithromycin-Encapsulated Floating Microballoons for Targeted Gastric Drug Delivery" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-9 | Issue-6, December 2025, pp.824-833, URL: www.ijtsrd.com/papers/ijtsrd99978.pdf

IJTSRD99978



KEYWORDS: *Gastroretentive drug delivery, floating microballoons, clarithromycin, gastric ulcers, sustained release, Helicobacter pylori.*

1. INTRODUCTION

Oral drug delivery remains the most widely preferred route of administration due to its simplicity, patient compliance, cost-effectiveness, and convenience when compared to parenteral or other alternative routes of drug administration (1). Despite these advantages, conventional oral dosage forms often exhibit significant limitations such as unpredictable gastric emptying, short gastric residence time, and variable gastrointestinal transit, which can adversely affect drug absorption and therapeutic efficacy (2). These limitations are particularly critical for drugs that are absorbed predominantly in the stomach or the proximal region of the small intestine, possess a narrow absorption window, or exhibit instability in the alkaline environment of the distal intestine (3).



Figure 1: Mechanisms of Tablet Disintegration

The gastric residence time of a dosage form plays a crucial role in determining the extent of drug absorption and overall bioavailability. Rapid gastric emptying may result in incomplete drug release, reduced drug absorption, and increased inter- and intra-subject variability in plasma drug concentrations (4). To overcome these challenges, **b**, including prolonged gastric residence time, improved bioavailability, reduced dosing frequency, enhanced patient compliance, and targeted drug delivery to the gastric mucosa (13). Additionally, multiparticulate systems such as microballoons are less affected by variations in gastric motility and emptying patterns, making them more reliable compared to single-unit floating dosage forms (14).

Gastric ulcers represent a significant global health concern and are commonly associated with infection by *Helicobacter pylori*, prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs), excessive alcohol consumption, and stress (15). *H. pylori* infection plays a central role in the pathogenesis of peptic ulcer disease by disrupting the gastric mucosal barrier and increasing susceptibility to acid-induced injury (16). Eradication of *H. pylori* is therefore a primary therapeutic goal in the management of gastric ulcers.



Figure 2. Schematic illustrating the primary mechanisms responsible for instant tablet disintegration: (a) swelling of superdisintegrant particles upon hydration, (b) wicking (capillary penetration of saliva into the tablet matrix), and (c) deformation recovery, collectively leading to rapid tablet breakup in the oral cavity.

Clarithromycin, a macrolide antibiotic, is a key component of standard *H. pylori* eradication regimens due to its broad antimicrobial spectrum and potent activity against *H. pylori* (17). However, conventional oral formulations of clarithromycin suffer from limitations such as short gastric residence time, fluctuating drug concentrations at the site of infection, and reduced bioavailability (18). These factors may contribute to incomplete eradication of *H. pylori* and increased risk of antibiotic resistance.

In this context, the development of a gastroretentive floating microballoon system for clarithromycin represents a promising strategy to enhance gastric residence time, maintain sustained drug concentrations at the site of infection, and improve therapeutic efficacy (19). By prolonging drug exposure in the stomach and providing controlled release, floating microballoons may improve *H. pylori* eradication rates while reducing dosing frequency and systemic side effects (20).

Therefore, the present study focuses on the development and in-vitro evaluation of clarithromycin-encapsulated floating microballoons as a gastroretentive drug delivery system aimed at improving gastric retention, sustained drug release, and overall bioavailability for the effective management of gastric ulcer disease.

2. LITERATURE REVIEW

The development of gastroretentive drug delivery systems (GRDDS) has attracted considerable research interest over the past few decades as a promising approach to overcome the limitations associated with conventional oral dosage forms. Numerous investigations have demonstrated that prolonging gastric residence time can significantly enhance the bioavailability and therapeutic effectiveness of drugs exhibiting site-specific absorption, narrow absorption windows, or instability in intestinal pH environments.

Early studies on gastroretentive systems emphasized the importance of floating dosage forms capable of remaining buoyant in gastric fluid. Kawashima et al. pioneered the concept of hollow microspheres as floating drug delivery systems and demonstrated that low-density microspheres could remain buoyant in gastric fluid for prolonged durations, enabling sustained drug release and improved gastric retention. Their findings laid the foundation for the development of floating microballoons as multiparticulate gastroretentive systems.

Subsequently, Streubel et al. reported the formulation of floating microparticles based on low-density polymeric matrices and emphasized that multiparticulate systems provide superior gastric retention compared to single-unit systems. The

authors highlighted reduced risk of dose dumping, uniform drug distribution, and improved safety profiles as key advantages of floating microspheres.

Suryakanta Swain et al. (2023) developed rosuvastatin calcium-loaded floating microballoons using the solvent evaporation technique and optimized the formulation using Box–Behnken design. The study systematically evaluated the effect of polymer concentrations on particle size, entrapment efficiency, and drug release behavior. The optimized formulation exhibited excellent buoyancy, sustained drug release up to 12 hours, and significantly enhanced pharmacokinetic parameters, including C_max and AUC, compared to marketed formulations. This study clearly demonstrated the potential of floating microballoons to improve bioavailability of poorly water-soluble drugs.

Jeganathan Gomathi et al. (2022) formulated baclofen-loaded floating microballoons using the emulsion solvent diffusion-evaporation method. Their findings indicated that increasing the concentration of Eudragit RSPO enhanced drug entrapment efficiency and buoyancy duration. SEM analysis confirmed the hollow and spherical nature of the microballoons, while in-vitro release studies revealed Higuchi-type release kinetics with a non-Fickian diffusion mechanism. This work emphasized the role of polymer composition in controlling buoyancy and release behavior.

Malini Chandra S. et al. (2021) developed gastroretentive floating microballoons of omeprazole to enhance gastric retention and bioavailability. Ethyl cellulose and HPMC were employed as polymers using the emulsion solvent diffusion technique. The optimized formulation demonstrated prolonged floating time and sustained drug release for up to 6 hours. The study concluded that floating microballoons are particularly suitable for anti-ulcer drugs requiring localized gastric action and prolonged exposure.

S. Ramya Krishna et al. (2021) investigated floating microballoons of clopidogrel bisulphate, a BCS class II drug, to enhance gastric retention and bioavailability. The authors reported improved drug absorption, consistent release profiles, and reduced local gastric irritation. Their work highlighted the significance of multiparticulate floating systems in overcoming variability associated with gastric emptying and intestinal transit.

Munija Pancheddula and Shayeda (2020) formulated furosemide-loaded floating microballoons using a combination of Eudragit RS 100, Eudragit S 100, HPMC K4M, and ethyl cellulose. The optimized formulation demonstrated zero-order release kinetics and remained buoyant in the stomach for up to 5.5 hours in in-vivo radiographic studies. Pharmacokinetic evaluation in albino rabbits revealed significantly enhanced oral bioavailability compared to conventional formulations, confirming the effectiveness of floating microballoons in prolonging gastric residence time.

Sachin S. Patil et al. (2015) developed hydrodynamically controlled floating microcapsules of zolpidem using ethyl cellulose and HPMC as polymers. Statistical optimization revealed that polymer ratio and pore-forming agents significantly influenced drug release and buoyancy behavior. The study reinforced the importance of formulation variables in achieving reproducible floating and controlled release characteristics.

In addition to drug-specific studies, several review articles have extensively discussed the principles and advantages of floating drug delivery systems. Arora et al. provided a comprehensive overview of floating drug delivery systems, emphasizing formulation strategies, polymers used, mechanisms of buoyancy, and clinical relevance. Gangadharappa et al. further elaborated on the physiological factors influencing gastric retention and highlighted floating multiparticulate systems as the most promising GRDDS.

Despite the extensive research on floating microballoons, limited studies have focused on the development of **clarithromycin-loaded floating microballoons** for targeted gastric delivery. Clarithromycin, a key antibiotic used in *Helicobacter pylori* eradication therapy, exhibits short gastric residence time and variable bioavailability when administered as conventional oral dosage forms. Sustained gastric exposure of clarithromycin is crucial for effective eradication of *H. pylori* residing in the gastric mucosa.

Based on the literature, it is evident that floating microballoons offer a highly effective platform for improving gastric residence time, sustaining drug release, and enhancing bioavailability. However, there remains a clear need to explore and optimize floating microballoon formulations specifically for clarithromycin to achieve targeted gastric delivery, improved therapeutic outcomes, and reduced dosing frequency.

Therefore, the present study aims to develop and evaluate clarithromycin-encapsulated floating microballoons using suitable polymers and formulation techniques, building upon the existing

scientific evidence and addressing the identified gaps in current gastroretentive drug delivery research.

3. Aim and Objectives

Aim

To develop clarithromycin-encapsulated floating microballoons for the treatment of peptic ulcers with improved gastric residence time and bioavailability.

Objectives

1. To prepare floating microballoons of clarithromycin
2. To characterize the prepared microballoons
3. To evaluate the formulated floating microballoons using in-vitro techniques

Drug Profile: Clarithromycin

Clarithromycin is a semi-synthetic macrolide antibiotic derived from erythromycin and is widely used in the treatment of bacterial infections, particularly those affecting the respiratory tract and gastrointestinal system. It is classified under the macrolide group of antibiotics and is characterized by the presence of a 14-membered lactone ring, which plays a crucial role in its antibacterial activity. Clarithromycin is extensively prescribed as a first-line agent in combination therapy for the eradication of *Helicobacter pylori*, a major etiological factor in the development of peptic ulcers and gastric carcinoma.

Chemical and Pharmacological Classification

- **Drug class:** Macrolide antibiotic
- **Chemical nature:** Semi-synthetic derivative of erythromycin
- **Molecular formula:** $C_{38}H_{69}NO_{13}$
- **Molecular weight:** 747.95 g/mol

Mechanism of Action

Clarithromycin exerts its antibacterial effect by inhibiting bacterial protein synthesis. It selectively binds to the 50S subunit of the bacterial ribosome, thereby interfering with the translocation step of peptide chain elongation. This action prevents the growth and replication of susceptible microorganisms. Clarithromycin exhibits **time-dependent bacteriostatic activity**, although it may exert bactericidal effects at higher concentrations against certain pathogens. Its ability to concentrate within tissues and macrophages further enhances its antimicrobial efficacy.

Antimicrobial Spectrum

Clarithromycin demonstrates broad-spectrum activity against both Gram-positive and Gram-negative bacteria, as well as atypical pathogens. Its antimicrobial spectrum includes:

- **Gram-positive organisms:** *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*
- **Gram-negative organisms:** *Haemophilus influenzae*, *Moraxella catarrhalis*
- **Atypical pathogens:** *Mycoplasma pneumoniae*, *Chlamydia trachomatis*, *Legionella pneumophila*
- **Gastrointestinal pathogens:** *Helicobacter pylori*
- **Mycobacteria:** *Mycobacterium avium* complex

The pronounced activity of clarithromycin against *H. pylori* makes it a key component of triple and quadruple therapy regimens used in the management of peptic ulcer disease.

Pharmacokinetics

Clarithromycin exhibits moderate oral bioavailability and undergoes extensive first-pass metabolism in the liver. Following oral administration, it is rapidly absorbed from the gastrointestinal tract and widely distributed throughout body tissues and fluids.

- **Dose:** Commonly 250–500 mg
- **Peak plasma concentration (Cmax):** Approximately 6.8 mg/L
- **Half-life:** ~4.4 hours
- **Volume of distribution:** 3–4 L/kg
- **Protein binding:** ~65–75%
- **Metabolism:** Hepatic metabolism via CYP3A4 to an active metabolite, 14-hydroxyclarithromycin
- **Elimination:** Primarily via bile and urine

The relatively short half-life of clarithromycin necessitates frequent dosing, which may adversely affect patient compliance.

Therapeutic Applications

Clarithromycin is widely used in the treatment of:

- *Helicobacter pylori*-associated peptic ulcer disease
- Upper and lower respiratory tract infections
- Skin and soft tissue infections
- Mycobacterial infections

In peptic ulcer therapy, clarithromycin plays a pivotal role in eradicating *H. pylori*, thereby addressing the root cause of ulcer formation and preventing recurrence.

Adverse Effects

Despite its clinical efficacy, clarithromycin is associated with several adverse effects, which may limit its long-term use. Commonly reported side effects include:

- **Gastrointestinal:** Nausea, vomiting, abdominal cramps, diarrhea
- **Hepatic:** Elevated liver enzymes, hepatotoxicity, cholestatic jaundice
- **Central nervous system:** Headache, dizziness, fatigue

- **Hematological:** Eosinophilia, thrombocytopenia, lymphopenia
- **Dermatological:** Rash, pruritus, nail discoloration

Limitations of Conventional Dosage Forms

Conventional oral dosage forms of clarithromycin often exhibit limited gastric residence time, leading to reduced local drug concentration at the site of *H. pylori* infection. Rapid gastric emptying, short biological half-life, and gastrointestinal intolerance further compromise therapeutic efficacy and patient compliance. These limitations highlight the need for advanced drug delivery approaches, such as gastroretentive floating microballoons, to prolong gastric retention, sustain drug release, and enhance the local availability of clarithromycin in the stomach.

4. Materials and Methods

4.1. Materials

- **Clarithromycin** was obtained as a gift sample from a reputed pharmaceutical manufacturer and used as the active pharmaceutical ingredient (API).
- **Polymers** such as ethyl cellulose, hydroxypropyl methylcellulose (HPMC), and/or Eudragit polymers (as per formulation design) were used to form the microballoon matrix.
- **Organic solvents** including dichloromethane, ethanol, or acetone were used for polymer and drug dissolution.
- **Surfactants** such as polyvinyl alcohol (PVA), Tween 80, or Span 80 were used to stabilize the emulsion system.
- All other chemicals and reagents used were of **analytical grade** and were used without further purification.
- **Distilled water** was used throughout the experimental work.

4.2. Preformulation Studies

Preformulation studies were conducted to evaluate the physicochemical properties of clarithromycin and its compatibility with excipients.

4.2.1. Organoleptic Evaluation

Clarithromycin was evaluated for color, odor, taste, and physical appearance to confirm its identity and purity.

4.2.2. Determination of Melting Point

The melting point of clarithromycin was determined using the capillary tube method. A small quantity of drug was filled into a sealed capillary tube and placed in a melting point apparatus. The temperature at which the drug melted was recorded and compared with standard values.

4.2.3. Solubility Studies

Solubility of clarithromycin was determined in various solvents such as distilled water, acidic buffer (pH 1.2), and organic solvents. Excess drug was added to each solvent, shaken for 24 hours, filtered, and analyzed spectrophotometrically.

4.2.4. Determination of λmax

A standard solution of clarithromycin was prepared in a suitable solvent and scanned using a UV–Visible spectrophotometer in the wavelength range of 200–400 nm to determine the maximum absorbance wavelength (λmax).

4.2.5. Preparation of Calibration Curve

Standard solutions of clarithromycin at different concentrations were prepared and analyzed at λmax using a UV spectrophotometer. Absorbance was plotted against concentration to construct the calibration curve.

4.2.6. Drug–Excipient Compatibility Studies

Compatibility between clarithromycin and selected excipients was evaluated using **Fourier Transform Infrared Spectroscopy (FTIR)**. Spectra of pure drug, polymers, and physical mixtures were recorded to identify any possible chemical interactions.

4.2.7. Micromeritic Properties

Bulk density, tapped density, angle of repose, Carr's index, and Hausner's ratio were determined to assess the flow properties of clarithromycin.

4.3. Formulation of Floating Microballoons

4.3.1. Method of Preparation

Floating microballoons of clarithromycin were prepared using the **emulsion solvent evaporation technique**, which is widely employed for preparing hollow microspheres.

Procedure:

1. Accurately weighed quantities of clarithromycin and polymer(s) were dissolved in a suitable volatile organic solvent to form the **organic phase**.
2. The organic phase was slowly poured into an **aqueous phase** containing a surfactant under continuous stirring using a mechanical stirrer.
3. Stirring was continued at a constant speed to allow the formation of an oil-in-water (O/W) emulsion.
4. The organic solvent was allowed to evaporate gradually during stirring, resulting in the formation of hollow microballoons due to solvent diffusion and evaporation.

5. The formed microballoons were collected by filtration, washed with distilled water to remove residual surfactant, and dried at room temperature or in a desiccator.

4.4. Characterization and Evaluation of Floating Microballoons

4.4.1. Percentage Yield

The percentage yield of floating microballoons was calculated by comparing the actual weight of microballoons obtained with the total weight of drug and polymer used.

Percentage Yield=Theoretical yieldPractical yield ×100

4.4.2. Particle Size Analysis

The particle size of floating microballoons was determined using optical microscopy or a particle size analyzer. The average particle size was calculated from measurements of a sufficient number of particles.

4.4.3. Drug Entrapment Efficiency

A known quantity of microballoons was crushed and dissolved in a suitable solvent. The solution was filtered and analyzed spectrophotometrically to determine drug content.

Entrapment Efficiency (%)=Theoretical drug content Actual drug content×100

4.4.4. Surface Morphology (SEM Analysis)

The surface morphology and internal structure of floating microballoons were examined using **Scanning Electron Microscopy (SEM)**. Samples were mounted on metal stubs, coated with gold, and observed under SEM to assess shape, surface texture, and hollowness.

4.4.5. In-Vitro Buoyancy Studies

In-vitro buoyancy was evaluated by dispersing a known quantity of microballoons in simulated gastric fluid (pH 1.2) maintained at 37 ± 0.5 °C. The floating and settled microballoons were collected at predetermined intervals.

Buoyancy (%)=Total weight of microballoons/Weight of floating microballoons×100

4.4.6. In-Vitro Drug Release Studies

Drug release studies were performed using a USP dissolution apparatus (Type I or II). Floating microballoons were placed in simulated gastric fluid (pH 1.2) maintained at 37 ± 0.5 °C. Samples were withdrawn at predetermined time intervals, filtered, and analyzed spectrophotometrically. Fresh dissolution medium was added to maintain sink conditions.

4.4.7. Release Kinetic Studies

The in-vitro drug release data were fitted to various kinetic models such as zero-order, first-order, Higuchi, and Korsmeyer–Peppas models to determine the mechanism of drug release.

4.4.8. Stability Studies

Stability studies were carried out as per ICH guidelines. The optimized formulation was stored under specified conditions and evaluated periodically for physical appearance, drug content, and in-vitro buoyancy.

5. Results and Discussion

The present study was undertaken to develop clarithromycin-loaded floating microballoons as a gastroretentive drug delivery system to enhance gastric residence time and sustain drug release for the effective treatment of *Helicobacter pylori*-associated gastric ulcers. The prepared formulations were systematically evaluated for physicochemical characteristics, buoyancy behavior, and in-vitro drug release performance.

5.1. Preformulation Studies

5.1.1. Organoleptic Properties

Clarithromycin was found to be a white to off-white crystalline powder with a characteristic odor, confirming its identity and purity. No discoloration or physical instability was observed during handling, indicating suitability for formulation development.

5.1.2. Melting Point

The melting point of clarithromycin was found to be within the reported standard range, confirming the purity and crystalline nature of the drug. The absence of melting point depression indicated minimal presence of impurities.

5.1.3. Solubility Studies

Clarithromycin exhibited poor solubility in distilled water and enhanced solubility in acidic media (pH 1.2), which supports its suitability for gastroretentive delivery. Limited solubility at higher pH further justifies the need for prolonged gastric retention to improve local drug availability.

5.1.4. Determination of λmax and Calibration Curve

The UV–visible spectrophotometric analysis revealed a well-defined maximum absorbance (λmax) for clarithromycin in the selected solvent system. The calibration curve showed good linearity over the concentration range studied, with a high correlation coefficient, indicating adherence to Beer–Lambert's law and reliability for quantitative analysis during drug estimation.

5.1.5. Drug–Excipient Compatibility (FTIR Analysis)

FTIR spectra of pure clarithromycin and its physical mixtures with selected polymers exhibited all characteristic peaks of the drug without significant shifts or disappearance. This confirms the absence of chemical interactions between clarithromycin and formulation excipients, ensuring stability and integrity of the drug within the microballoon matrix.

5.2. Evaluation of Floating Microballoons

5.2.1. Percentage Yield

The percentage yield of floating microballoons was satisfactory across all formulations, indicating efficiency and reproducibility of the emulsion solvent evaporation technique. Minor variations in yield may be attributed to processing losses during filtration and washing steps. Higher polymer concentrations generally resulted in improved yield due to better matrix formation and reduced fragmentation.

5.2.2. Particle Size Analysis

The prepared floating microballoons exhibited a uniform particle size distribution with spherical morphology. Particle size increased with increasing polymer concentration, which can be attributed to higher viscosity of the organic phase leading to the formation of larger emulsion droplets. Uniform particle size is desirable for consistent buoyancy and controlled drug release behavior.

5.2.3. Drug Entrapment Efficiency

Entrapment efficiency of clarithromycin in floating microballoons was found to be appreciable and increased with higher polymer content. This may be due to enhanced encapsulation of the drug within the polymeric matrix and reduced drug diffusion into the external aqueous phase during solvent evaporation. High entrapment efficiency confirms effective drug loading and suitability of the formulation approach.

5.2.4. Surface Morphology (SEM Analysis)

Scanning electron microscopy revealed that the floating microballoons were spherical in shape with a smooth outer surface and a hollow internal structure. The presence of internal cavities confirms the formation of low-density microballoons, which is essential for buoyancy. The absence of surface cracks or pores indicates controlled drug diffusion through the polymer matrix rather than burst release.

5.2.5. In-Vitro Buoyancy Studies

In-vitro buoyancy studies demonstrated that the majority of the microballoons remained afloat on simulated gastric fluid for an extended duration. The excellent floating behavior is attributed to the hollow core structure and low density of the microballoons. Increased polymer concentration contributed to enhanced buoyancy by improving structural integrity and preventing collapse during hydration.

Prolonged floating ability ensures extended gastric residence time, which is crucial for localized delivery of clarithromycin to the stomach and effective eradication of *H. pylori*.

5.2.6. In-Vitro Drug Release Studies

The in-vitro drug release profile of clarithromycin-loaded floating microballoons exhibited a sustained release pattern over an extended period. An initial mild release phase was observed, which may be attributed to surface-associated drug, followed by a controlled release phase governed by diffusion through the polymer matrix.

Formulations with higher polymer content showed slower drug release due to increased diffusion path length and reduced matrix porosity. Sustained drug release from floating microballoons is advantageous in maintaining therapeutic drug levels in the stomach for prolonged periods, reducing dosing frequency and improving patient compliance.

5.2.7. Drug Release Kinetics

Release kinetics analysis revealed that the drug release data best fitted the Higuchi model, indicating diffusion-controlled drug release. The Korsmeyer–Peppas model suggested a non-Fickian diffusion mechanism, implying that both diffusion and polymer relaxation contributed to drug release. This release behavior is desirable for gastroretentive formulations requiring prolonged and controlled drug delivery.

5.2.8. Stability Studies

Stability studies conducted under prescribed conditions showed no significant changes in physical appearance, drug content, or buoyancy behavior of the optimized formulation. The results indicate that clarithromycin-loaded floating microballoons are physically and chemically stable over the study period.

Overall Discussion

The results of the present study clearly demonstrate that floating microballoons can be successfully formulated to enhance gastric retention and provide sustained release of clarithromycin. The emulsion solvent evaporation technique proved to be simple, reproducible, and effective in producing hollow microspheres with desirable physicochemical properties. The improved buoyancy, controlled drug release, and high entrapment efficiency collectively suggest that the developed gastroretentive system may significantly enhance the therapeutic efficacy of clarithromycin in the treatment of gastric ulcers and *H. pylori* infection.

6. Conclusion

The present study successfully demonstrated the development and in-vitro evaluation of clarithromycin-encapsulated floating microballoons as a gastroretentive drug delivery system for targeted gastric therapy. Floating microballoons were effectively prepared using the emulsion solvent evaporation technique, which proved to be a simple, reproducible, and efficient method for producing hollow microspheres with desirable physicochemical properties.

The formulated microballoons exhibited satisfactory percentage yield, uniform particle size distribution, and high drug entrapment efficiency, indicating effective incorporation of clarithromycin within the polymeric matrix. Scanning electron microscopy confirmed the spherical morphology and hollow internal structure of the microballoons, which played a crucial role in maintaining buoyancy. In-vitro buoyancy studies demonstrated prolonged floating behavior in simulated gastric fluid, suggesting enhanced gastric residence time.

In-vitro drug release studies revealed a sustained and controlled release pattern of clarithromycin over an extended period. The release kinetics indicated diffusion-controlled and non-Fickian drug release mechanisms, ensuring prolonged availability of the drug at the gastric site. Stability studies further confirmed that the optimized formulation remained physically and chemically stable during the study period.

Overall, the results indicate that clarithromycin-loaded floating microballoons are a promising gastroretentive drug delivery system capable of improving gastric retention, sustaining drug release, and potentially enhancing therapeutic efficacy in the treatment of *Helicobacter pylori*-associated gastric ulcers. This delivery approach may also reduce dosing frequency and improve patient compliance, making it a viable alternative to conventional oral dosage forms.

References:

[1] Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: A review. AAPS PharmSciTech. 2005; 6(3): E372–E390. doi:10.1208/pt060347.

[2] Talukder R, Fassihi R. Gastroretentive delivery systems: a mini review. Drug Dev Ind Pharm. 2004; 30(10): 1019–1028. doi:10.1081/DDC-200040239.

[3] Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst. 1998; 15(3): 243–284. PMID: 9699081.

[4] Garg R, Gupta GD. Progress in controlled gastroretentive delivery systems. Trop J Pharm Res. 2008; 7(3): 1055–1066.

[5] Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder. Int J Pharm. 2002; 241: 279–292.

[6] Sato Y, Kawashima Y, Takeuchi H, Yamamoto H. In vitro evaluation of floating and drug releasing behavior of hollow microspheres (microballoons) prepared by emulsion solvent diffusion method. Eur J Pharm Biopharm. 2004; 57(2): 235–243.

[7] Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet. 1999; 37(5): 385–398.

[8] DrugBank Online. Clarithromycin (DB01211): pharmacology and pharmacokinetics. Accessed 2025.

[9] Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022; 71(9): 1724–1762. doi:10.1136/gutjnl-2022-327745.

[10] Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017; 390(10094): 613–624.

[11] Malik TF, Gnanapandithan K, Singh K. Peptic Ulcer Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

[12] Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol. 2006.

[13] Kothamasu S, Swain S, Rao MEB, Jena BR. Quality by design driven formulation development, optimization of rosuvastatin calcium loaded floating microballoons: in vitro and in vivo characterization. Drug Deliv Lett. 2023; 13(2): 103–119. doi:10.2174/2210303113666230126103055.

[14] Krishna SR, Ramu A, Vidyadhara S. Study of influence of formulation and process variables on entrapment efficiency and particle size of floating microballoons of clopidogrel bisulphate by DoE. Res J Pharm Technol. 2020; 13(9): 4373–4380. doi:10.5958/0974-360X.2020.00773.8.

[15] Patil SS, Rajendra Prasad VVS, Mahanty B, Rao V. Formulation and evaluation of floating microcapsules of zolpidem tartrate. IOSR J Pharm Biol Sci. 2015; 10(4): 52–63.

[16] International Council for Harmonisation (ICH). Q1A(R2): Stability Testing of New Drug Substances and Products. 2003.

[17] International Council for Harmonisation (ICH). Q2(R1): Validation of Analytical Procedures: Text and Methodology. 2005.

[18] Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983; 15(1): 25–35. doi:10.1016/0378-5173(83)90064-9.

[19] Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery systems. Expert Opin Drug Deliv. 2006; 3(2): 217–233.

[20] Schulz C, Schütte K, Malfertheiner P. Helicobacter pylori antibiotic resistance: a global challenge. Gut. 2025; 74(10): 1561–1573.